Diabetic Gastroparesis Treatment Market Growth Trends: Moderate Expansion with 6.3% CAGR Until 2030

 The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Is the Growth Potential of the Diabetic Ketoacidosis (DKA) Market in the Next Decade?
The diabetic gastroparesis treatment market size has grown strongly in recent years. It will grow from $4.05 billion in 2025 to $4.28 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising diabetes complications, limited historical treatment options, increasing diagnosis rates, reliance on pharmacological management, growth in gastroenterology specialty care.

The diabetic gastroparesis treatment market size is expected to see strong growth in the next few years. It will grow to $5.47 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to development of novel prokinetic agents, increased disease awareness, expansion of specialty clinics, demand for long-term symptom control, innovation in gastric stimulation technologies. Major trends in the forecast period include increasing use of prokinetic drug therapies, rising focus on symptom-based disease management, expansion of combination pharmacological treatments, growing adoption of minimally invasive interventions, increased emphasis on dietary and lifestyle management.

Claim your free report sample now:
Diabetic Gastroparesis Treatment Market 2026, Trends And Insights Sample

What Are the Key Market Drivers and Opportunities in the Diabetic Gastroparesis Treatment Market?
The increasing prevalence of diabetes is expected to propel the growth of the diabetic gastroparesis treatment market going forward. The prevalence of diabetes refers to the proportion or percentage of the population that has been diagnosed with diabetes at a specific point in time. The use of diabetic gastroparesis treatment is primarily aimed at managing the symptoms and complications associated with this condition, which is a common complication of diabetes. For instance, in April 2025, according to the International Diabetes Federation, a Belgium-based international not-for-profit federation of national diabetes associations, an estimated 589 million adults aged 20–79 were living with diabetes worldwide, with that number projected to reach 853 million by 2050. Therefore, the increasing prevalence of diabetes is driving the growth of the diabetic gastroparesis treatment market.



What Are the Emerging Segments in the Diabetic Gastroparesis Treatment Market?
The diabetic gastroparesis treatment market covered in this report is segmented –

1) By Treatment: Medication, Surgery
2) By Route Of Administration: Oral, Injectables
3) By Indication: Compensated Gastroparesis, Gastric Failure
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Medication: Prokinetic Agents, Antiemetics, Antidepressants
2) By Surgery: Gastric Electrical Stimulation, Surgical Procedures For Gastric Drainage

Which Trends Are Expected to Redefine the Diabetic Gastroparesis Treatment Market Landscape?
Major companies operating in the diabetic gastroparesis treatment market are innovating advanced solutions, such as small bowel intubation, to enhance diagnostic accuracy and treatment effectiveness. Small bowel intubation involves inserting a tube into the small intestine, enabling more precise monitoring and therapeutic interventions for conditions like diabetic gastroparesis, where gastric motility is impaired. For instance, in September 2024, Avenacy, a US-based pharmaceutical company launched Metoclopramide Injection (USP) in Unites States. Metoclopramide Injection (USP) is an injectable medication designed for multiple indications, notably including the relief of symptoms associated with diabetic gastroparesis. It helps prevent nausea and vomiting related to chemotherapy and surgery. The injection assists in small bowel intubation in cases where conventional methods fail to pass a tube through the pylorus. It is used to stimulate gastric emptying and facilitate barium transit during radiological procedures.

Which Major Companies Are Operating in the Diabetic Gastroparesis Treatment Market?
Major companies operating in the diabetic gastroparesis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Ipca Laboratories Ltd., Abbott Laboratories, AstraZeneca plc, Medtronics plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Janssen Global Services LLC, Boston Scientific Corporation, Fresenius Kabi AG, Bausch Health Companies Inc., Salix Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Wockhardt Ltd., ANI Pharmaceuticals Inc., Endologic LLC, Vanda Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Theravance Biopharma Inc., Neurogastrx Inc., Evoke Pharma Inc., CinRx Pharma LLC

Get the full diabetic gastroparesis treatment market report here:
https://www.thebusinessresearchcompany.com/report/diabetic-gastroparesis-treatment-global-market-report

Which Region Is Projected to Account for the Largest Share of the Diabetic Gastroparesis Treatment Market?
North America was the largest region in the diabetic gastroparesis treatment market in 2025, and is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic gastroparesis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

#Contact Us:#

The Business Research Company: Market Research Reports
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

#Follow Us On:#

LinkedIn: The Business Research Company | LinkedIn